Moleculin Biotech (MBRX) Stock: Breaking Out Now | Here’s Why!

Moleculin Biotech Inc (NASDAQ: MBRX)

Moleculin Biotech is having an incredible day in the market today, and for good reason. The company released a PR that reminded investors of an important call that’s coming soon. Today, we’ll talk about the call, what we’re seeing from the stock, and why this call is going to be incredibly important for MBRX investors.

Trade smarter and make more money with Tradespoon!

MBRX Reminds Investors Of Important Call

Early this morning, Moleculin Biotech published a press release reminding investors about an important call. The company will be hosting a conference call with a focus on discussing “positive developments regarding Annamycin.” Annamycin is a drug candidate that MBRX is developing for the treatment of Acute Myeloid Leukemia. The company also said that they will be providing a corporate update on the call.

Call Information

If you would like to take part in the MBRX call, it is open to the masses. To access the call, use the information below:

  • Call Time – October 20, 2016 5:00PM Eastern.
  • Call In Number – Toll Free (877) 418-3859 | Local (412) 902-6506
  • Participant Entry Number – 4494430

How The Stock Is Reacting To The News

As investors, we know that the news moves the market. Ultimately, investors seem to be taking an overwhelmingly positive stance on this particular news. While we don’t know exactly what is going to be released, the fact that the company will be discussing “positive developments regarding Annamycin” suggests that investors can expect to see something great. As a result, we’re seeing big gains in the market today. Currently (1:58), the stock is trading at $3.83 per share after a gain of $1.14 per share (42.55%) thus far today.

Why This Call Is So Important

There are several reasons this call is overwhelmingly important for MBRX investors. First and foremost, as a pre-clinical and clinical stage biotechnology company, the data is what will move the needle for the stock. Another big piece here is that, if the data is indeed positive, it signals that the company is one step closer to approval for commercialization. Outside of the investing side of things, AML is a serious condition for which few options are available to patients and their families. Not only is MBRX doing something that could generate big profits in the future with Annamycin, if this data is positive, it may signal hope for AML patients and their families.

Don’t waste your time! Click here to find winning trades in minutes!

Never Miss The News Again

You want the news fast, we dig it up in real time and get it to you. It’s all free for a limited time. All you need to do is subscribe below!

Subscribe to our mailing list

* indicates required

[Image Courtesy of Wikipedia]

Leave a Comment